Lu Chunwan, Makala Levi, Wu Daqing, Cai Yafei
College of Life Sciences,Anhui Normal University,Key Laboratory of Biotic Environment and Ecological Safety in Anhui Province,Wuhu 241000,Anhui,China.
Cancer Center,Medical College of Georgia,Georgia Regents University,Augusta,GA 30912,USA.
Expert Rev Mol Med. 2016 Jan 18;18:e2. doi: 10.1017/erm.2015.20.
The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.
翻译起始因子eIF4E介导一个限速过程，该过程驱动许多致癌蛋白（如细胞周期蛋白D1、生存素和血管内皮生长因子）的选择性翻译，从而促进肿瘤生长、转移和治疗抗性。作为癌症信号网络中的一个关键调控枢纽，许多致癌信号通路似乎都汇聚于eIF4E。因此，靶向eIF4E介导的帽依赖性翻译被认为是一种很有前景的抗癌策略。本文综述了可用于靶向eIF4E的策略，重点介绍了在每个不同水平靶向eIF4E活性的药物。
